CL2020003252A1 - Compuestos de cianotriazol y usos de los mismos - Google Patents

Compuestos de cianotriazol y usos de los mismos

Info

Publication number
CL2020003252A1
CL2020003252A1 CL2020003252A CL2020003252A CL2020003252A1 CL 2020003252 A1 CL2020003252 A1 CL 2020003252A1 CL 2020003252 A CL2020003252 A CL 2020003252A CL 2020003252 A CL2020003252 A CL 2020003252A CL 2020003252 A1 CL2020003252 A1 CL 2020003252A1
Authority
CL
Chile
Prior art keywords
compounds
present
cyanotriazole
cyanotriazole compounds
compositions
Prior art date
Application number
CL2020003252A
Other languages
English (en)
Inventor
Jan Jiricek
Shuyi Pearly Ng
Srinivasa P S Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020003252A1 publication Critical patent/CL2020003252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención proporciona un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo: (I) en donde R1, R2, R3, y R4 han sido definidos en la presente. La presente invención además proporciona usos terapéuticos de estos compuestos, por ejemplo contra la tripanosomiasis africana humana; composiciones farmacéuticas que comprenden estos compuestos y composiciones que comprenden estos compuestos con un coagente terapéutico.
CL2020003252A 2018-06-19 2020-12-16 Compuestos de cianotriazol y usos de los mismos CL2020003252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687045P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
CL2020003252A1 true CL2020003252A1 (es) 2021-07-09

Family

ID=67841115

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003252A CL2020003252A1 (es) 2018-06-19 2020-12-16 Compuestos de cianotriazol y usos de los mismos

Country Status (21)

Country Link
US (1) US20220106296A1 (es)
EP (1) EP3810598A1 (es)
JP (1) JP2021528397A (es)
KR (1) KR20210022646A (es)
CN (1) CN112313217A (es)
AU (1) AU2019291490B2 (es)
BR (1) BR112020025538A2 (es)
CA (1) CA3100954A1 (es)
CL (1) CL2020003252A1 (es)
CR (1) CR20200619A (es)
CU (1) CU20200102A7 (es)
EA (1) EA202190064A1 (es)
EC (1) ECSP20080991A (es)
IL (1) IL279483A (es)
JO (1) JOP20200327A1 (es)
MA (1) MA52977A (es)
MX (1) MX2020013729A (es)
PE (1) PE20210780A1 (es)
PH (1) PH12020552186A1 (es)
SG (1) SG11202012628XA (es)
WO (1) WO2019244049A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115181060B (zh) * 2022-08-19 2024-03-19 江苏禾裕泰化学有限公司 一种生产2-氨基-3-氯-5-三氟甲基吡啶的清洁生产工艺
CN116284772B (zh) * 2023-02-09 2024-02-27 四川大学 一种联吡啶三唑共价有机聚合物及其制备方法和应用
CN116836111A (zh) * 2023-09-01 2023-10-03 峰成医药科技(天津)有限公司 一种氟代吡啶的连续化合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
EP2790705B1 (en) * 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
US20170368034A1 (en) * 2014-12-22 2017-12-28 Glaxosmithkline Intellectual Property Development Limited Thiotriazole compound and its use in parasitic protozoal infections

Also Published As

Publication number Publication date
PE20210780A1 (es) 2021-04-21
WO2019244049A1 (en) 2019-12-26
MX2020013729A (es) 2021-05-12
IL279483A (en) 2021-01-31
BR112020025538A2 (pt) 2021-03-16
JP2021528397A (ja) 2021-10-21
CR20200619A (es) 2021-01-21
CN112313217A (zh) 2021-02-02
US20220106296A1 (en) 2022-04-07
SG11202012628XA (en) 2021-01-28
JOP20200327A1 (ar) 2020-12-15
ECSP20080991A (es) 2021-02-26
EA202190064A1 (ru) 2021-03-29
AU2019291490B2 (en) 2022-02-10
CU20200102A7 (es) 2021-08-06
PH12020552186A1 (en) 2021-06-07
MA52977A (fr) 2021-04-28
AU2019291490A1 (en) 2021-02-04
CA3100954A1 (en) 2019-12-26
KR20210022646A (ko) 2021-03-03
EP3810598A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
CL2020003252A1 (es) Compuestos de cianotriazol y usos de los mismos
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
UY37941A (es) Derivados de bencimidazol y sus usos
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
PH12016501198A1 (en) Compounds and compositions for the treatment of parasitic diseases
ECSP23095674A (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
EA201992754A1 (ru) Фармацевтические композиции